EGFR and non-small cell lung carcinoma: Ramalingam et al. [77] reported a phase III clinical trial of 556 patients with previously untreated advanced NSCLC with an EGFR mutation who received either osimertinib or other EGFR TK inhibitors (i.e., gefitinib or erlotinib).